Granules India gets Health Canada nod to market arthritis tablets

Drug firm Granules India on Monday said it has received marketing nod from Health Canada for its Acetaminophen extended-release tablets used in the treatment of arthritis pain. The company has received approval from Health Canada for Acetaminophen extended-release tablets OTC, 650 mg, Granules India said in a regulatory filing.

“We received the approval within eight months of filing. This is a step towards global expansion of our core molecules. The approval of Acetaminophen extended-release tablets OTC, 650mg…, is a good addition to our portfolio,” Granules USA, Inc & Granules Pharmaceuticals, Inc Executive Director Priyanka Chigurupati said.

The company will be launching the product in Canadian market soon, she added.

The drug will be manufactured at the company’s manufacturing facility located in GagillapurHyderabad, the filing said.

Shares of Granules India Ltd were trading at Rs 335.90 per scrip on BSE, up 1.53 per cent from its previous close.

  • Related Posts

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by week 1 and sustained through study end, alongside low rates of…

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    After substandard drug manufacturing, the state drug firms are once again under the scanner of the central government for manufacture and sale of unapproved fixed dose combination (FDC) drugs which…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise